Outcome of Treatment of Deep-Vein Thrombosis with Urokinase: Relationship to Dosage, Duration of Therapy, Age of the Thrombus and Laboratory Changes

Summary

Forty-one patients with phlebographically proven DVT of the popliteal, femoral or iliac veins were treated with different regimens of urokinase (UK) given by continuous intravenous infusion. The four groups were comparable with respect to localization, extension and estimated age of the thrombi. Another phlebographic picture was taken within 48 hr after the end of UK infusion. Substantial lysis had occurred in 2 of 10 patients treated with 1500 U/kg/h for 2 days, in 4 of 11 treated with 2500/U/kg/h for 3 days, in 2 of 10 treated with 2500 U/kg/h for 7 days and in 4 of 10 treated with 4000 U/kg/h for 4 days. Only thrombi younger than 8 days could be lysed, with 61% (8/13) rate of lysis for thrombi less than 5 days old. Bleeding complications were observed more frequently with the higher doses and longer durations of therapy. The four treatment regimens all induced dose-dependent changes in fibrinogen, fibrin(ogen) degradation products, plasminogen and antiplasmin. Neither pre- nor postinfusion values of these parameters could differentiate patients with lysis from those without lysis. It is concluded that UK can provoke a high rate of thrombolysis of DVT treated early after the appearance of symptoms but that there is no relationship between UK-induced modifications of fibrinolysis and the outcome of therapy.

Keywords

Urokinase - Thrombolytic therapy - Streptokinase - Deep-vein thrombosis

• References

• 1 Hansen PF, Jørgensen M, Kjeldgaard NO, Ploug J. Urokinase - an activator of plasminogen from human urine. Experiences with intravenous application on twenty-two patients Angiology 1961; 12: 367-371
• 2 Fletcher AP, Alkjaersig N, Sherry S, Genton E, Hirsh J, Bachmann F. The development of urokinase as a thrombolytic agent. Maintenance of a sustained thrombolytic state in man by its intravenous infusion J Lab Clin Med 1965; 65: 713-731
• 3 Silver D. Urokinase in the management of acute arterial and venous thrombosis. Arch Surg 1968; 97: 910-916
• 4 Mavor GE, Ogston D, Galloway JM D, Karmody AM. Urokinase in iliofemoral venous thrombosis. Br J Surg 1969; 56: 571-574
• 5 Theiss W, Kriessmann A, Wirtzfeld A. Laborbefunde und klinische Ergebnisse bei thrombolytischer Langzeittherapie mit Urokinase. Herz/Kreis 1975; 7: 631-636
• 6 Sharma GV R K, O’Connell DJ, Belko JS, Sasahara AA. Thrombolytic therapy in deep vein thrombosis. In: Thrombosis and Urokinase. Paoletti R, Sherry S. (eds) Academic Press; London: 1977. pp 181-189
• 7 Tilsner V. Therapie mit Urokinase bei thrombotischen Verschliissen der Venen. In: Urokinase Workshop. Tilsner V. (ed) Papillon; Freiburg: 1978. pp 103-119
• 8 Trübestein G, Brecht T, Etzel F. Ergebnisse der fibrinolytischen Therapie mit Urokinase bei älteren Phlebothrombosen. Dtsch Med Wschr 1979; 104: 1241-1242
• 9 Juhan I, Calas MF, Buonocore M, Mathieu P, Isnard G, Cazenave B, Serradimigni A. Modifications in coagulation parameters induced by treatment associating urokinase (2000 U CTA/kg/h) with heparin. Thromb Haemostas 1979; 42: 945-954
• 10 Niessner H, Lechner K, Thaler E. Laboratory and clinical evaluation of five urokinase schemes in acute and subacute deep vein thrombosis: a non-randomized study in 34 patients. In: Urokinase: Basic and Clinical Aspects. Mannucci PM, D’Angelo A. (eds) Academic Press; New York: 1982. pp 111-119
• 11 Schöffel G, Zimmermann R, Harenberg J, Mori H. Blood coagulation changes during effective thrombolysis using urokinase and heparin. Thromb Res 1982; 25: 11-21
• 12 Thrombolytic therapy in thrombosis: a National Institutes of Health Consensus Development Conference. Ann Intern Med 1980; 93: 141-144
• 13 Bieger R, Boekhout-Mussert RJ, Hohmann F, Loeliger EM. Is streptokinase useful in the treatment of deep vein thrombosis. Acta Med Scand 1976; 199: 81-83
• 14 Brandenberg E, Widmer MT, Schmitt HE, Widmer LK. Venenthrombose und postthrombotisches Syndrom. 5-Jahres-follow-up bei 278 Patienten. In: Fibrinolytische Therapie. Triibestein G, Etzel F. (eds) Schattauer; Stuttgart: 1983. pp 295-297
• 15 Vermylen C, De Vreeker RA, Verstraete M. A quick quantitative enzymatic fibrinogen assay method: the fibrin polymerisation time (FPT). Clin Chim Acta 1963; 8: 428-434
• 16 Hawiger J, Niewiarowski S, Gurewich V, Thomas DP. Measurement of fibrinogen and fibrin degradation products in serum by staphylococcal clumping test. J Lab Clin Med 1970; 75: 93-108
• 17 Abildgaard V, Lie M, Odegaard OR. Antihrombin (heparin cofactor) assay with »new« chromogenic substrates (S-2238 and Chromozym Th). Thromb Res 1977; 11: 549-553
• 18 Soria J, Soria C, Samama M. A plasminogen assay using a chromogenic synthetic substrate: results from clinical work and from studies of thrombolysis. In: Progress in Chemical Fibrinolysis and Thrombolysis. Vol.3. Davidson JF, Samama M, Desnoyers PC. (eds) Raven Press; New York: 1978. pp 337-346
• 19 Teger-Nilsson AC, Friberger P, Gyzander E. Determination of a new rapid plasmin inhibitor in human blood by means of a plasmin specific tripeptide substrate. Scand J Clin Lab Invest 1977; 37: 403-409
• 20 Mannucci PM, Sirchia G, Federici AB. Hemostasis testing during massive blood replacement. A study of 172 cases Vox Sang 1982; 42: 113-123
• 21 Marbet GA, Eichlisberger R, Duckert F, Da Silva MA, Biland L, Widmer LK, Ritz R, Schmitt HE. Sequential treatment of deep leg vein thrombosis with porcine plasmin and low-dose streptokinase. Thromb Haemostas 1982; 48: 190-195
• 22 Theiss W, Wirtzfeld A, Fink U, Maubach P. The success rate of fibrinolytic therapy in fresh and old thrombosis of the iliac and femoral veins. Angiology 1983; 34: 61-69
• 23 Bell WR, Meek AG. Guidelines for the use of thrombolytic agents. N Engl J Med 1977; 301: 1266-1270
• 24 Marder VJ. The use of thrombolytic agents: Choice of patient, drug administration, laboratory monitoring. Ann Intern Med 1979; 90: 802-808
• 25 Dhall DP, Dawson AA, Mavor GE. Problems of resistant thrombolysis and early recurrent thrombosis in streptokinase therapy. Surg Gynecol Obstet 1978; 146: 15-20
• 26 Schmutzler R, Roller F. Thrombolytic therapy. In: Recent advances in blood coagulation. Poller P. (ed) Churchill Ltd; London: 1969. pp 299-335
• 27 Kakkar VV, Flanc C, Howe CT, O’Shea M, Flute PT. Treatment of deep vein thrombosis. A trial of heparin, streptokinase and arvin Br Med J 1969; 1: 806-810
• 28 Åstedt B, Robertson B, Haegar K. Experience with standardized streptokinase therapy of deep venous thrombosis. Surg Gynecol Obstet 1974; 139: 387-388
• 29 Marder VJ, Soulen RL, Atichartakarn V, Budzynski AZ, Parulekar S, Kim JR, Edward N, Zahavi J, Algazy KM. Quantitative venographic assessment of deep vein thrombosis in the evaluation of streptokinase and heparin therapy. J Lab Clin Med 1977; 89: 1018-1029
• 30 Duckert F, Muller G, Nyman D, Benz A, Prisender S, Madar G, Da Silva MA, Widmer LK, Schmitt HE. Treatment of deep vein thrombosis with streptokinase. Br Med J 1975; 1: 479-481
• 31 Tsapogas MJ, Peabody RA, Wu KT, Karmody AM, Devaraj KT, Eckert C. Controlled study of thrombolytic therapy in deep vein thrombosis. Surgery 1973; 74: 973-984
• 32 Conard J, Samama M. Laboratory control of SK therapy. In: Present status of thrombosis. Its pathophysiology, diagnosis and treatment. Losito R. (ed) Schattauer; Stuttgart: 1973. pp 191-198
• 33 Van de Loo JC W, Kriessmann A, Triibestein G, Knock K, de Swart CA M, Asbeck F, Marbet GA, Schmitt HE, Sewell AF, Duckert F, Theiss W, Ritz R. Controlled multicenter pilot study of urokinaseheparin and streptokinase in deep vein thrombosis. Thromb Haemostas 1983; 50: 660-663